RXi Pharmaceuticals and the Center for Cancer Immune Therapy (CCIT) at Herlev Hospital have entered into a collaborative research agreement to evaluate the potential of RXi's novel self-delivering RNAi (sd-rxRNA) technology platform in TILs for the use in treatment for a number of cancer types, including melanoma and ovarian cancer.
"Immunotherapy treatments have shown significant promise in extending the lifespan of previously untreatable cancer patients. We are excited to work with the extraordinary scientific leaders at the CCIT to evaluate the advantages of our therapeutic sd-rxRNA compounds in various cancer models," Dr. Karen Bulock, Vice President of Research at RXi Pharmaceuticals said. "This research collaboration, in combination with other collaborations we have announced, are going to be key cornerstones in our efforts to translate positive results into a clinical setting which we hope to achieve within the next 12-18 months."